Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery

被引:63
作者
Zaro, Jennica L. [1 ]
机构
[1] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90033 USA
关键词
drug delivery; fatty acids; glyceride; phospholipid; prodrug; LOW-DENSITY-LIPOPROTEIN; INTESTINAL LYMPHATIC TRANSPORT; HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO; TESTOSTERONE-UNDECANOATE; ANTITUMOR-ACTIVITY; INTRAVENOUS-INJECTION; BIOLOGICAL EVALUATION; LYMPHOID ORGANS; NUCLEIC-ACIDS;
D O I
10.1208/s12248-014-9670-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The combination of lipid drug delivery systems with prodrugs offers several advantages including improved pharmacokinetics, increased absorption, and facilitated targeting. Lipidization and use of lipid carriers can increase the pharmacological half-life of the drug, thus improving pharmacokinetics and allowing less frequent dosing. Lipids also offer advantages such as increased absorption through the intestines for oral drug absorption and to the CNS for brain delivery. Furthermore, the use of lipid delivery systems can enhance drug targeting. Endogenous proteins bind lipids in the blood and carry them to the liver to enable targeting of this organ. Drugs with significant side effects in the stomach can be specifically delivered to enterocytes by exploiting lipases for prodrug activation. Finally, lipids can be used to target the lymphatic system, thus bypassing the liver and avoiding first-pass metabolism. Lymphatic targeting is also important for antiviral drugs in the protection of B and T lymphocytes. In this review, both lipid-drug conjugates and lipid-based carriers will be discussed. An overview, including the chemistry and assembly of the systems, as well as examples from the clinic and in development, will be provided.
引用
收藏
页码:83 / 92
页数:10
相关论文
共 96 条
[1]   Troxacitabine prodrugs for pancreatic cancer [J].
Adema, A. D. ;
Radi, M. ;
Daft, J. ;
Narayanasamy, J. ;
Hoebe, E. K. ;
Alexander, L. E. ;
Chu, C. K. ;
Peters, G. J. .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2007, 26 (8-9) :1073-1077
[2]   Synthesis and biological evaluation of gemcitabine-lipid conjugate (NE06002) [J].
Ali, SM ;
Khan, AR ;
Ahmad, MU ;
Chen, P ;
Sheikh, S ;
Ahmad, I .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (10) :2571-2574
[3]   PHARMACOKINETICS OF STEALTH VERSUS CONVENTIONAL LIPOSOMES - EFFECT OF DOSE [J].
ALLEN, TM ;
HANSEN, C .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1068 (02) :133-141
[4]  
[Anonymous], 2007, PRODRUGS CHALLENGES
[5]  
[Anonymous], 1993, ADV LIPID METHODOLOG
[6]   Lipases, liposomes and lipid-prodrugs [J].
Arouri, Ahmad ;
Hansen, Anders Hojgaard ;
Rasmussen, Thomas Elmelund ;
Mouritsen, Ole G. .
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 2013, 18 (05) :419-431
[7]   Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts [J].
Bergman, AM ;
Kuiper, CM ;
Noordhuis, P ;
Smid, K ;
Voorn, DA ;
Comijn, EM ;
Myhren, F ;
Sandvold, ML ;
Hendriks, HR ;
Fodstad, O ;
Breistol, K ;
Peters, GJ .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9) :1329-1333
[8]   Synthesis and evaluation of 5' alkyl ester prodrugs of zidovudine for directed lymphatic delivery [J].
Bibby, DC ;
Charman, WN ;
Charman, SA ;
Iskander, MN ;
Porter, CJH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 144 (01) :61-70
[9]   SYNTHESIS OF THE DIOLEOYL DERIVATIVE OF IODODEOXYURIDINE AND ITS INCORPORATION INTO RECONSTITUTED HIGH-DENSITY-LIPOPROTEIN PARTICLES [J].
BIJSTERBOSCH, MK ;
SCHOUTEN, D ;
VANBERKEL, TJC .
BIOCHEMISTRY, 1994, 33 (47) :14073-14080
[10]  
Breistol K, 1999, CANCER RES, V59, P2944